A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Clin Lung Cancer. 2023 Jun;24(4):347-352. doi: 10.1016/j.cllc.2023.03.003. Epub 2023 Mar 21.
No abstract available

Keywords: Epigenetic modification; Platinum resistance; Relapsed small cell lung cancer.

Publication types

  • Clinical Trial, Phase II
  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Azacitidine / therapeutic use
  • Carboplatin / therapeutic use
  • Humans
  • Lung Neoplasms* / drug therapy
  • Small Cell Lung Carcinoma* / drug therapy

Substances

  • Carboplatin
  • guadecitabine
  • Azacitidine